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INTRODUCTION 
Ischemic stroke is one of the common diseases found in medical wards, and is 
one of the common causes of morbidity and mortality worldwide. There are 
many causes of ischemic stroke and hyperhomocysteinemia is one of the 
documented causes. Homocysteine is synthesised in our body from methionine 
in a multistep process. Many vitamins like folic acid, vit B12, pyridoxine are 
involved in the homocysteine biosynthesis. Hyperhomocysteinemia is a 
proatherosclerotic state which is due to many pathological mechanisms. 
Homocysteine more than 15 µmol/L is taken as hyperhomocysteinemia. It has 
also been implicated in various other diseases like cardiovascular diseases, 
neuropsychiatric disorders, pregnancy complications, etc. There are many 
causes for hyperhomocysteinemia of which nutritional deficiencies and genetic 
causes are the most common. Treatment of hyperhomocysteinemia mainly 
involes nutritional supplementation with folic acid and Vit.B12, and others.  
Carotid intima media thickness (CIMT)measurement is accepted as a method to 
identify atherosclerosis, as increased CIMT has been found to be associated 
with increased cardiovascular and cerebrovascular complications. It is measured 
routinely by B-mode USG. CIMT has been found to be increased in 
hyperhomocysteinemia as well.   
 
 
AIMS AND OBJECTIVES 
1. To study the clinical profile of ischemic stroke at Government Stanley 
Hospital, Chennai. 
2. To study prevalence of hyperhomocysteinemia in these patients and correlate 
with carotid intima media thickness in these patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
Place of study: 
Department of general medicine,  medical OPD and medical wards,  Stanley 
medical college and hospital, Chennai. 
Duration: 
November 2013 to September 2014. 
Study design: 
Prospective  observational study 
Patient selection: 
Any patient with  ischemic stroke in medical OPD and medical wards.  
 
Sample size : 
75 patients 
 
Ethical committee approval 
Ethical committee approval was obtained for the study  
 
 
 
Methodology 
Patients admitted with symptoms suggestive of ischemic stroke, which is 
proved later by CT brain, will undergo serum homocysteine measurements and 
carotid USG to measure carotid intima media thickness. The study will be 
aimed at observing the prevalence of hyperhomocysteinemia in ischemic stroke 
and also whether there is any correlation between the serum homocysteine 
levels and carotid intima media thickness. 
 
Exclusion criteria: 
Hemorrhagic stroke, patients on folic acid supplements, patients on anti-
epileptics/ OCPs/ drugs causing hyperhomocysteinemia, chronic kidney disease, 
pre-existing coronary artery disease 
 
 
 
 
 
 
 
Stastical analysis 
Data will be analysed with SPSS software version 16.0 for windows.  
All continuous data will be expressed as mean and sd and will be analysed using 
students t test.  
Categorical data will be expressed as number (percentage) and analysed by chi 
square or fishers exact test.  
Pearson's correlation coefficient and linear regression analysis will be 
undertaken to establish correlation and regression among variables.  
P value of <0.05 was considered as statistically significant 
 
 
 
 
 
 
 
 
CONSENT 
The study group thus identified by the above criteria (inclusion and exclusion 
criteria) was first instructed about the nature of the study. Willing participants 
were taken up for this study after getting a written / informed consent from these 
patients or their relatives in the local vernacular language. 
STUDY SUBJECTS 
All   the  patients  who  fulfilled  the  inclusion  criteria were  included  in  this  
study. The  included  patients were subjected to detailed history taking, 
complete physical examination  and  the  relevant  laboratory  investigations  as 
per a proforma, exclusively  designed  for  the  study. 
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I. INTRODUCTION 
Ischemic stroke is one of the common diseases found in medical wards, and is 
one of the common causes of morbidity and mortality worldwide. There are 
many causes of ischemic stroke and hyperhomocysteinemia is one of the 
documented causes. Homocysteine is synthesised in our body from methionine 
in a multistep process. Many vitamins like folic acid, vit B12, pyridoxine are 
involved in the homocysteine biosynthesis. Hyperhomocysteinemia is a 
proatherosclerotic state which is due to many pathological mechanisms. 
Homocysteine more than 15 µmol/L is taken as hyperhomocysteinemia. It has 
also been implicated in various other diseases like cardiovascular diseases, 
neuropsychiatric disorders, pregnancy complications, etc. There are many 
causes for hyperhomocysteinemia of which nutritional deficiencies and genetic 
causes are the most common. Treatment of hyperhomocysteinemia mainly 
involes nutritional supplementation with folic acid and Vit.B12, and others.  
Carotid intima media thickness (CIMT)measurement is accepted as a method to 
identify atherosclerosis, as increased CIMT has been found to be associated 
with increased cardiovascular and cerebrovascular complications. It is measured 
routinely by B-mode USG. CIMT has been found to be increased in 
hyperhomocysteinemia as well.   
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II. REVIEW OF LITERATURE 
HOMOCYSTEINE 
Homocysteine is a sulphur containing amino acid and each molecule of 
homocysteine contains one atom of sulphur. 
It is a homologue of cysteine and it differs from cysteine by an additional 
methylene bridge (-CH2-). 
Homocysteine is synthesised from methionine by the removal of its terminal 
methyl group. 
Elevated levels of homocysteine in the blood, called hyperhomocysteinemia, 
has been implicated in the pathogenesis of many diseases like cardiovascular 
disease, stroke, pregnancy problems, osteoporosis, Alzheimer’s, schizophrenia 
and others. 
 
HISTORY 
Butz and du Vigneaud discovered homocysteine in 1932. They heated 
methionine in sulphuric acid and incidentally produced homocysteine as a 
result. 
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Dr. Kilmer McCully came up with the hypothesis in mid 1960s that moderate 
elevations of homocysteine can lead to strokes and heart attacks. But this theory 
was not accepted then. 
Later, in mid 90s, by the work of Dr. Meir Stampfer, researchers accepted that 
homocysteine was an independent risk factor for strokes and cardiovascular 
disease. 
 
BIOCHEMISTRY 
Molecular formula - C4H9NO2S 
Chemical nomenclature - 2-Amino-4-sulfanylbutanoic acid 
Molar mass – 135.18 mg/mol 
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At neutral pH values, homocysteine exists as a zwitterion or a dipolar ion 
 
BIOSYNTHESIS 
 
Homocysteine is not available from the diet. It is synthesised in the body from 
methionine via a multi-step process. 
1. Methionine initially gets an adenosine group from ATP and this reaction 
is catalysed by the enzyme S-adenosyl methionine synthetase, to form S-
adenosyl methionine (SAM) 
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2. The methyl group of SAM is then transferres to an acceptor molecule, to 
form S-adenosyl homocysteine. 
3. Then hydrolysis of the adenosine yields Homocysteine 
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Homocysteine thus formed can enter 2 pathways : 
1. Cysteine biosynthesis via Transsulfuration – homocysteine is condensed 
with serine by the enzyme cystathione β synthase to form cystathionine. 
Pyridoxine is needed as a co-factor for this reaction. Cystathionine is then 
converted into cysteine by cystathionine γ lyase. Ammonia and alpha-
keto glutarate are also formed along with cysteine.       
2. Methionine salvage – homocysteine is converted back into methionine by 
the enzyme Methionine synthase. This enzyme needs N5 methyl 
tetrahydrofolate as methyl donor and vitamin B12. 
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Other minor roles – 
 Homocysteine can also form homocysteine thiolactone 
 Homocysteine is an allosteric antagonist at dopamine receptors (D2) 
 
So, vitamins B6,B12 and folate are essential for metabolism of homocysteine. If 
a person ingests a protein rich food and his diet is deficient in these vitamins, 
his homocysteine levels in the blood will rise and can cause 
hyperhomocysteinemia , which in turn can lead to further complications. 
 
 
HYPERHOMOCYSTEINEMIA 
Abnormal levels of homocysteine in serum more than 15  µmol/L is defined as 
hyperhomocysteinemia 
It can be further classified as : 
 Mild hyperhomocysteinemia  -  15 – 30 µmol/L 
 Moderate hyperhomocysteinemia -  30 – 100 µmol/L 
 Severe hyperhomocysteinemia  -  >100 µmol/L 
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Hyperhomocysteinemia has been implicated in the pathogenesis of various 
diseases like myocardial infarction, stroke, osteoporosis, neuropsychiatric 
disorders, alzheimers, pregnancy complications and many other diseases. 
There are many diseases, drugs and other factors which can lead to an increased 
level of homocysteine in the blood.  
Genetic mutations to various enzymes involved in metabolism or synthesis of 
homocysteine will also lead to hyperhomocysteinemia. 
Vitamin deficiencies ( folate, vitamin B12, pyridoxine ) are one of the common 
causes of this condition. 
Old age, male gender, smoking and  alcoholism are also related to increasing 
homocysteine levels in blood. 
Other conditions including various medical disorders like chronic kidney 
disease, psoriasis and SLE also are implicated for hyperhomocysteinemia. 
Drugs like antiepileptics (phenytoin, carbamazepine), methotrexate, nicotinic 
acid, etc are also common causes of hyperhomocysteinemia. 
 
 
 
 
9 
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CAUSES OF HYPERHOMOCYSTEINEMIA :
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GENETIC CAUSES : 
Most common genetic cause of hyperhomocysteinemia is a 5-
Methyltetrahydrofolate reductase (MTHFR) defect. 9-17% of the population is 
homozygous for this mutant enzyme whereas heterozygosity is seen in 30-41% 
of the general population.  
The MTHFR gene is on chromosome 1 (1p36.3) and the 2 most common 
studied mutations are the  C677T and A1298C single nucleotide 
polymorphisms (SNP). 
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Homozygous deficiencies of cystathionine β synthase causes homocystinuria , 
which is characterised  by mental retardation, premature atherosclerosis and 
venous & arterial thrombosis.  
These patients will have severe hyperhomocysteinemia with serum 
homocysteine levels more than 300 µmol/L.  
Heterozygous deficiency of this enzyme is more common than homozygous, 
and it causes moderate hyperhomocysteinemia. 
Diminished activity of methionine synthase will also cause 
hyperhomocysteinemia, and this condition is associated with birth defects, 
blindness and neurological symptoms. 
 
VITAMIN DEFICIENCIES :  
Folic acid, vitamin B12 and pyridoxine act as cofactors or cosubstrates in 
various enzymatic reactions in homocysteine biosynthesis and metabolism. So 
patients with low levels of folate and vit. B12 , hyperhomocysteinemia has been 
detected. 
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OTHER CAUSES : 
Homocysteine levels in blood increase with increasing age. 
Males have been found to have higher homocysteine levels when compared to 
their female counterparts. 
Tobacco use, smoking and alcoholism also increase blood homocysteine levels. 
Homocysteine levels were found to be elevated in patients with chronic kidney 
disease, SLE, deep vein thrombosis, solid organ transplantation and psoriasis. 
Many commonly used drugs like phenytoin, carbamazepine, methotrexate, 
nicotinic acid, thiazides, nitrous oxide and colestipol also increase blood 
homocysteine levels. 
It has also been found to get elevated during an acute phase of a systemic 
illness. 
 
 
PATHOPHYSIOLOGY AND PATHOGENESIS 
 
Hyperhomocysteinemia causes various vascular and haematological 
abnormalities which lead to the formation of a prothrombotic and 
proatherogenic metabolic milieu. 
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The various abnormalities seen are – 
1. Endothelial cell injury – it is the first step in the initiation of atherosclerosis. 
It is manifested as – a) impaired NO and EDHF dependent vasodilation, b) 
decreased activity of tissue type plasminogen activator, c) endothelial 
lipidosis and  d) increased smooth muscle proliferation. 
 
 
 
2. Clotting cascade abnormalities – a) inhibition of natural anticoagulants like 
factor C and antithrombin III, b) activation of factors V, X and XII 
3. Homocysteine increases binding of lipoprotein a to fibrin, which stimulates 
the smooth muscle cell proliferation. 
4. Homocysteine levels are related to the serum fibrinogen levels, which in 
itself is also a separate risk factor for atherosclerosis. 
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5. Increased platelet aggregation - due to increased thromboxane A2 synthesis 
and decreased prostacyclin production 
6. Homocysteine decreases release of nitric oxide 
7. It also produces reactive oxygen species which also cause endothelial 
dysfunction. 
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 PATHOPHYSIOLOGICAL FINDINGS 
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It has also been postulated that hyperhomocysteinemia exerts its pathogenic 
effects due to a molecule -  S-adenosyl-L-homocysteine (SAH), which gets 
accumulated . 
SAH is a strong noncompetitive inhibitor of COMT (catechol-O-methyl 
transferase). COMT is involved in the  metabolism of various catechol 
substrates like catecholamines and catechol estrogens.  
This will result in increase in blood / tissue levels of catecholamines.  
The vasculature is thus exposed to large levels of these catecholamines. Hence 
the vascular endothelial cells undergo chronic cumulative damage caused by the 
excess oxidative products produced by the catecholamines. 
This explains why hyperhomocysteinemia is an increased risk actor for 
cardiovascular as well as neurodegenerative diseases. 
 
Excess homocysteine can also be converted into homocysteine thiolactone, 
which is a highly reactive intermediate which thiolates free aminogroups in 
LDL and cause them to aggregate and get endocytosed by macrophages. These 
lipid deposits form atheromas. 
Homocysteine can also react with lysyl aldehyde groups on collagen and block 
them, and binds to fibrillin 1, causing Marfan like symptoms. 
 
19 
 
EPIDEMIOLOGY IN INDIA : 
When compared to the west, Indian studies which examined the prevalence of 
hyperhomocysteinemia in the Indian community have reported a much higher 
incidence in the range of 52 to 84%. The mean homocysteine levels are also 
quiet high, ranging from 19.5 to 23.2 µmol/L. 
 In India, marked hyperhomocysteinemia has been observed with markedly 
decreased intake of vitamin B12 and folic acid in the vegetarians and urban 
middle class people. 
 Low plasma concentrations of folate, vitamins B-6 and B-12,male gender, older 
age, and urban life were all independently associated with elevated 
homocysteine levels, with low folate as the strongest determinant. 
Although majority of Indians are vegetarian, there is also a high incidence of 
folate deficiency reported. The reason for this has been found that Indians 
usually cook their food for longer duration, which can destroy nearly 90% of the 
folic acid. 
 Pyridoxine deficiency has been found to be quite common among Indians. 
Another factor that predisposes Indians to hyperhomocysteinemia is the genetic 
defect in the enzymes that metabolize homocysteine. 
 Many studies have found that nearly one-third of Indians have a genetic defect 
which leads to decreased activity of MTHFR.  
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There are two polymorphisms of the MTHFR enzyme which are common 
amongst Indians, they are the C677T and A1298C polymorphisms.  
In a study, the presence of either of the polymorphisms was examined, and they 
found that 43.5% of the population had decreased MTHFR activity. 
However, compared to diet ,the effect of genetic factors in increasing the 
homocysteine level seemed to be modest. 
 
LAB MEASUREMENT OF HOMOCYSTEINE 
Physiologically, homocysteine exists as oxidised, reduced and protein bound 
forms. The initial methods introduced in mid 80s resolved these problems ( 
presence of multiple homocysteine forms in the plasma ) by converting all the 
species into the reduced form, which was an indicator of total homocysteine. 
Later, modern methods used pretreatment of plasma specimens with reducing 
agents like dithiothreitol, dithioerythritol, mercaptoethanol, tributylphosphine or 
tris(2 carboxylethyl) phosphine which converted all the homocysteine species 
into the reduced form. 
Modern total homocysteine measurement methods include enzyme 
immunoassays and chromatography based methods. 
Immunoassays are the most commonly used technique for routine purposes. 
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Most of the research studies have measured Homocysteine levels using high-
performance liquid chromatography (HPLC). 
In HPLC, Homocysteine can be seen as a fluorescent derivative. 
Electrochemical detection of homocysteine is also possible. 
Competitive immunoassays for Homocysteine have been developed, on a 
variety of instruments in the clinical laboratory. These are also now available in 
many labs nowadays.  
These assays have been based on the quantitative enzymatic conversion of 
Homocysteine to the molecule  S-adenosyl homocysteine ( SAH ).  
Many antibodies have been produced that specifically recognize this compound, 
therefore competitive assay of the concentration of S-adenosylhomocysteine 
was easily measured.  
Recent development of simple calorimetric enzyme assays for Homocysteine 
has allowed analyses to be performed on routine clinical biochemistry 
analyzers. 
 These assays are based on either  on enzymatic release of hydrogen sulfide 
which reacts to form a chromogen or an enzymatic cycling assay. 
 Tandem mass spectrometry is another option for analysis of Homocysteine. 
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Method comparisons showed that there were relatively small variations between 
different methods. Hence all methods offer sufficient analytical performance for 
routine clinical use; therefore ,choice of method usually will be based on 
practical considerations of efficiency,cost and labour, and on which analyzers 
are available in the laboratory. 
Blood samples have to be taken in test tubes containing an anticoagulant like 
EDTA and should be centrifuged as early as possible,before 30 minutes, to 
avoid false positive homocysteine values, as it can be released from red blood 
cells.  
Some  patients may have abnormal homocysteine metabolism . Because of this 
problem, these patients may have normal fasting plasma homocysteine levels, a 
flase negative test, and hence they require a provocative testing – called 
methionine loading  test - to bring out this problem. 
Methionine loading test – administer 100 mg/kg of methionine orally, later, 
after around 6-8 hours, measure the plasma homocysteine levels.  
According to various studies, it has been shown that the methionine loading test 
identifies nearly an additional 27% of hyperhomocysteinemia cases. 
But since this methionine loading test is costly and time consuming, and also 
since there is inter individual variation in the time needed for peak 
homocysteine levels, the role of this test in routine clinical practice is 
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controversial. And most of the studies based on hyperhomocysteinemia and 
atherosclerotic vascular disease measured only the fasting plasma homocysteine 
levels. So the methionine loading test may be done once its efficacy is proved 
without doubt. 
  
SCREENING FOR HYPERHOMOCYSTEINEMIA 
Screening for hyperhomocysteinemia may be advised for those people who are 
at high risk for developing premature atherosclerotic vascular disease and those 
persons who are having risk factors for developing hyperhomocysteinemia.  
These patients include those with : 
(1) atherosclerotic vascular disease patients without conventional risk factors 
(2) premature atherosclerotic vascular disease (ie.before 60 years of age) 
(3) premature atherosclerotic vascular disease in a first-degree relative  
(4) atherosclerotic vascular disease risk factors related to 
hyperhomocysteinemia, like smoking, hypertension ,old age ,etc 
(5) chronic renal failure patients 
(6) systemic lupus erythematosus  
(7) unexplained deep venous thrombosis 
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(8) solid organ transplantation  
(9) severe psoriasis 
(10) prolonged use of medications causing hyperhomocysteinemia 
 
TREATMENT OF HYPERHOMOCYSTEINEMIA 
Dietary and lifestyle modifications : 
1. Avoid methionine rich foods like dairy products and red meat 
2. Exercise  
3. Stop alcohol, smoking and coffee 
4. Weight loss 
5. Avoid drugs causing hyperhomocysteinemia 
Drug therapy : 
1. Vitamin supplementation – folic acid, vit.B12, vit.B6 
2. N-acetyl cysteine 
3. Omega 3 PUFAs 
4. Taurine supplementation 
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5. Trimethylglycine and choline supplementation 
6. S-adenosyl-L-methionine supplementation 
7. Riboflavin supplementation 
 
VITAMIN SUPPLEMENTATION : 
Treatment with folic acid of doses 400 µg or more daily has been found to 
lower homocysteine levels by 30% to 42%.  Lower doses have not been found 
to be very effective in lowering homocysteine levels. 
Vitamin B12 supplementation has also been found to decrease serum 
homocysteine levels by around 15%. 
Pyridoxine hydrochloride supplementation, in the absence of vit B6 deficiency, 
was not found to significantly lower the serum homocysteine levels. 
When all these 3 vitamins were given combinedly, orally or as a once monthly 
intramuscular injection, it was found to lower the homocysteine levels by 15-
72%. 
Since the combination of vit B6 and B12 with folic acid has a better effect in 
patients with low vit B6 or B12 levels, a combined therapy with all 3 vitamins is 
preferred for the treatment of hyperhomocysteinemia.  
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Also, when folate is given alone, it masks the vit. B12 deficiency. Various 
complications of vit B12 deficiency like subacute combined degeneration of 
spinal cord can be hence prevented with vit B12 supplementation. 
The American Heart and Stroke Association advised to treat patients having 
stroke and hyperhomocysteinemia with 0.4 mg of folic acid, 2.4 µg of vitamin 
B12 and 1.7 mg of vitamin B6 daily. 
 
N-Acetyl-Cysteine  
Research studies have found that N-acetyl-cysteine (NAC) has a            
homocysteine lowering effect. Usage of this drug can  lead to a highly 
significant reduction in atherosclerotic vascular events. This is attributable to 
the improvement of endothelial function by the homocysteine lowering ability 
of NAC. NAC promotes the formation of cysteine from homocysteine and also 
produces NAC disulphide molecules during the process, and these 2 molecules 
are easily excreted via the kidneys, and thus homocysteine levels in blood can 
be lowered. 
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Omega-3 PUFAs  
Many researches have found that omega-3 fatty acids lower homocysteine 
levels. Therefore fish oils which are rich in omega-3 fatty acids can be given for 
treating hyperhomocysteinemia. 
Taurine  
It has been found that the amino acid taurine decreases methionine absorption 
from the diet, which in turn leads to less production of homocysteine in the 
body. Therefore, supplementation with taurine can decrease atherosclerotic 
vascular disease by lowering homocysteine levels in the blood. 
Trimethylglycine (TMG) and Choline  
TMG ( Betaine ) which was discovered from sugar beets, acts as a methyl donor 
in the homocysteine metabolism pathway, in the reaction where homocysteine 
is converted back into methionine. So more homocysteine is salvaged back into 
methionine, thereby lowering homocysteine levels. 
Choline gets metabolised into TMG in our body.  
Hence supplementation of TMG and choline can be useful in lowering serum 
homocysteine levels. These have been found to be useful for preventing 
atherosclerosis. 
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SAMe 
SAMe (S-adenosyl-L-methionine), is a molecule which is directly involved in 
the synthesis and metabolism of homocysteine. It is  biosynthesized from 
methionine and ATP. It also helps in conversion of homocysteine back into 
methionine as it acts as a methyl donor itself.  
Nutritional supplementation of SAMe is useful for hyperhomocysteinemia, as it  
also promotes the conversion of homocysteine to glutathione and cysteine. 
SAMe supplements also increase the activity of 5-MTHF, which converts 
homocysteine back into methionine. 
Riboflavin  
Vitamin B2 (riboflavin) has also been known to be a determinant of plasma 
homocysteine levels in individuals with a 5-MTHFR C677T gene variant. 
Hyperhomocysteinemia is highly responsive to riboflavin (since riboflavin is 
required as a co-factor by MTHFR), especially in individuals with the MTHFR 
C677T genotype. 
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CEREBROVASCULAR DISEASE 
Cerebrovascular diseases include the following disorders – ischemic stroke, 
hemorrhagic stroke, cerebrovascular anomalies like intracranial aneurysms, AV 
malformations, etc. 
 These diseases are a main cause for mortality as well as morbidity worldwide. 
Since the old age population is increasing (due to better medical care), the 
incidence of these diseases are also increasing, and they are more common in the 
older ages. 
These diseases usually present in the form of a focal neurological deficit. 
Stroke – a sudden onset of a neurological deficit , which is due to the interruption 
of blood supply to the brain, and which lasts for more than 24 hours. This results 
in damage to the brain tissue – cerebral ischemia. Neurological symptoms can be 
seen within seconds of blood supply disruption because neurons do not have 
glycogen and so energy failure occurs rapidly.  
Cerebral infarction , that is, death of the neurons and the brain tissue occurs if the 
disruption of blood supply to the brain lasts for many minutes. 
Ischemic stroke – caused by obstruction of blood flow in a vessel, caused by a 
thrombus or an embolus. 
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Hemorrhagic stroke – caused by bleeding from the blood vessels into or around 
the brain parenchyma. The symptoms and signs are caused by the blood itself or 
the mass effect of the bleed onto the surrounding brain structures or from 
increased intracranial tension. 
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Transient Ischemic Attack (TIA) - it has been dubbed as a ‘mini-stroke’, and it is 
defined as a transient episode of neurological deficit due to disruption of cerebral 
blood flow, but the neurological signs and symptoms resolve within 24 hours of 
onset. The diagnosis of TIA can be made even without imaging evidence of  brain 
injury. 
If the symptoms or signs persist for more than 24 hours, then we call it a stroke. 
Hypoxic ischemic encephalopathy – this occurs when there is global cerebral 
ischemia, which in turn deprives the brain of adequate oxygen supply leading to 
cerebral hypoxia. The consequent neurological sequelae that follows is termed 
Hypoxic ischemic encephalopathy. 
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BRAIN - ANATOMY  
The adult human brain, on average, weighs about 1.5 kg and has a volume of 
around 1130 cm3 in women and 1260 cm3 in men. 
                                   
 
The brain lies within the cranial cavity and it is continuous with with the spinal 
cord through foramen magnum. 
3 meninges surround the brain – the pia mater, arachnoid mater and the dura 
mater., which are continuous with the corresponding meninges of the spinal 
cord. The brain is surrounded by the cerebrospinal fluid in the subarachnoid 
space. 
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Anatomical division of brain can be done in several ways. The most common 
way of division is into 3 parts – Prosencephalon ( forebrain ),  Mesencephalon ( 
midbrain ) and Rhombencephalon ( hindbrain ) – and this is based on the 
embryonic development. 
 The forebrain (or Prosencephalon) is made up of the cerebrum, thalamus and 
the hypothalamus. The cerebrum makes up the Telencephalon and the thalamus 
and hypothalamus and the rest constitute the Diencephalon. 
 The midbrain (or Mesencephalon) is composed of the tectum (or corpora 
quadrigemina), the tegmentum, the cerebral aqueduct and the cerebral 
peduncles, which are part of the brainstem. 
 The hindbrain (or Rhombencephalon) consists of the pons, the medulla 
oblongata and  the cerebellum. The medulla forms the Myelencephalon and the 
pons & cerebellum form the Metencephalon. 
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The brain tissue consists of an inner core of white matter and a surrounding 
outer covering of gray matter. 
 Gray matter is mostly made of unmyelinated neurons, and most of them are 
interneurons. These gray matter regions are the main areas of nerve connections 
and processing. 
 White matter is mostly made of myelinated neurons which connect the regions 
of gray matter to each other and also to the rest of the body. These myelinated 
neurons can transmit nerve signals much faster than unmyelinated axons.So the 
white matter acts as the information highway of the brain, by speeding the 
connections between distant parts of the brain and also the body. 
 Certain important masses of gray matter are found deep inside within the white 
matter, eg. The cerebellar nuclei within the cerebellum, the gray thalamic, 
caudate and lentiform nuclei within the cerebrum. 
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Histology 
Brain cells can be divided into two groups: the neurons and the neuroglia. 
Neurons, or nerve cells, are those cells that perform all the communication and 
processing within the brain. Majority of the neurons in the brain’s gray matter 
are interneurons, and these neurons are responsible for integrating and 
processing information which are delivered to the brain by the sensory neurons. 
Sensory neurons which enter the brain from the peripheral nervous system 
deliver information regarding the condition of the body and its surroundings. 
Interneurons then send signals to the motor neurons, which  then carry signals to 
muscles and glands. 
Neuroglia, or glial cells, are the helper cells of the brain. These cells support 
and protect the neurons. There are four types of glial cells in the brain namely -
astrocytes, oligodendrocytes, microglia, and ependymal cells. 
 
 Astrocytes act by protecting neurons, by filtering nutrients out of the blood and 
also preventing pathogens and chemicals from leaving the capillaries of the 
brain. Astrocytes are the predominant building blocks for the blood brain 
barrier. 
 Oligodendrocytes act by wrapping the axons of neurons in the brain to produce 
an insulation known as myelin. These myelinated axons transmit nerve signals 
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much faster than unmyelinated ones, therefore oligodendrocytes accelerate the 
communication speed of the brain. 
 Microglia act similar to white blood cells by attacking and destroying pathogens 
that invade the brain. They are  specialized macrophages which are capable 
of phagocytosis thereby protecting neurons of the central nervous system.  
 Ependymal cells are those which line the capillaries of the choroid plexuses and 
produce cerebrospinal fluid. 
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CEREBRUM  
The cerebrum is  the largest part of the brain. It develops from the 
telencephalon. It lies in front or on top of the brainstem. In humans, it is the 
largest and best-developed part of the major divisions of the brain. The 
cerebrum is the phylogenetically newest structure in the brain. The surface layer 
of the cerebral hemispheres, that is the cortex, is thrown into folds or gyri, and 
are separated by fissures or sulci. This results in an increased surface area of the 
cerebral cortex. The largi sulci are used to subdivide the surface of the cerebral 
hemispheres into lobes. 
The cerebrum is made of the following regions: 
 Cerebral cortex  or the cortices of the cerebral hemispheres 
 Basal ganglia 
 Limbic System 
 
The limbic and  motor systems project fibres from the cerebrum to 
the brainstem and spinal cord. Cognitive systems project fibres from the 
cerebrum to the thalamus and to some specific regions of the midbrain. These 
neural networks of the cerebrum facilitate complex behaviors such as 
thought, judgement, social interactions, working memory, learning, 
speech and language. 
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LOBES 
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The cerebrum is divided into 4 lobes – 
1. Frontal lobe 
2. Parietal lobe 
3. Temporal lobe 
4. Occipital lobe 
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BRAIN CIRCULATION – ANATOMY  
The cerebral circulation has an arterial circulation and a venous drainage. 
The arterial circulation of the brain can be divided into : 
1. Anterior circulation 
2. Posterior circulation 
A stroke can occur involving either the anterior circulation, posterior circulation 
or both. 
The major artery in the anterior circulation is the internal carotid artery whereas 
the vertebral artery is the one for the posterior circulation. 
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ANTERIOR CIRCULATION 
Anterior circulation is by the 2 internal carotid arteries which lie in the 
subarachnoid space, and they anastomose with the vertebral artery branches on 
the inferior surface of the brain to form what is called the circle of willis. 
Internal carotid artery –  
It begins where the common carotid artery bifurcates into the external and 
internal carotid arteries , at c3-c5 level, where it has a localised dilatation called 
the carotid sinus. It ascends through the neck and enters the skull through the 
base of the skull and passes through the carotid canal of the temporal bone. 
Then it runs forward in the cavernous sinus before piercing the dura mater and 
emerging on the medial side of the anterior clinoid process. Here it pierces the 
arachnoid mater and enters the subarachnoid space  where it turns posteriorly 
towards the medial end of the lateral cerebral sulcus and there it divides into the 
anterior and middle cerebral arteries. 
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The internal carotid artery is divided into 4 portions based on its course : 
1. Cervical                                         
2. Petrous 
3. Cavernous 
4. Cerebral 
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Bouthellier also divided the internal carotid into 7 segments namely -  C1 
cervical, C2 petrous, C3 lacerum, C4 cavernous, C5 clinoid, C6 ophthalmic, and 
C7 communicating.  
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Branches of the cerebral segment : 
1. Ophthalmic artery – it is the first branch of the internal carotid, which is 
given off as the internal carotid leaves from the cavernous sinus. It is 
given off along the medial side of the anterior clinoid process and it 
enters the orbit through the optic canal with the optic nerve running 
inferolaterally. 
                          
Area of supply – eye, orbital structures, frontal area of scalp, dorsum of 
nose , frontal and ethmoid sinuses. 
Branches - Central retinal artery, Lacrimal artery, Posterior ciliary 
arteries, Muscular branches, Supraorbital artery, Ethmoidal arteries, 
Medial palpebral arteries, supratrochlear (frontal) artery and the dorsal 
nasal artery. 
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2. Posterior communicating artery 
It is a small blood vessel which takes off from the internal carotid artery 
very near its terminal bifurcation and it then runs posteriorly to join the 
posterior cerebral artery, thus it connects the anterior and posterior 
circulation and forms a part of the circle of willis. This artery functions 
like a collateral between the anterior and posterior circulations of the 
brain. 
3. Choroidal artery 
It originates from the posterior wall of the internal carotid near its 
terminal bifurcation and passes posteriorly near the optic tract, then it 
circumvents the cerebral peduncles to reach the lateral geniculate body. It 
enters the lateral ventricle and finally ends in the choroid plexus. It 
mainly supplies the lateral geniculate body, the crus cerebri , optic tract 
and internal capsule. 
4. Anterior cerebral artery 
It is one of the terminal branches of the internal carotid, along with the 
middle cerebral artery, and it is the smaller of the two. It runs forward, 
medially and superiorly to the optic nerve and enters the longitudinal 
fissure of the cerebrum, then curves backward and passes anterior to the 
genu of corpus callosum, and anastomoses with the posterior cerebral 
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artery. The anterior cerebral arteries on either side are interconnected by 
the anterior communicating artery. 
The cortical branches supply medial surface of cerebral cortex and a thin 
strip of the lateral surface as well.  It supplies most of the superior medial 
parietal lobes and parts of the frontal lobes. 
The central branches pierce the anterior perforated substance and supply 
the corpus callosum, the lentiform and caudate nuclei as well as the 
internal capsule.   
5. Middle cerebral artery 
It is the other terminal branch and the largest branch of the internal 
carotid artery. It runs laterally in the cerebral sulcus and divides into 
many cortical and central branches and mainly supply the lateral cortex 
and internal capsule. 
Cortical branches supply almost whole of lateral cerebral hemisphere 
except  for the superior inch of the frontal and parietal lobe (anterior 
cerebral artery supply), the occipital pole and inferolateral surface ( 
posterior cerebral artery supply ). 
Central branches supply the basal ganglia and internal capsule.                                   
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POSTERIOR CIRCULATION 
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Vertebral artery : 
The vertebral arteries arise from the 1st part of the subclavian artery, passes deep 
to the transverse processes of the 6th cervical vertebra, then ascends up the neck 
by passing through the foramina in the transverse processes of the above 
cervical vertebrae. They cross the posterior arch of C1 and pass in the 
suboccipital triangle before it enters the skull through the foramen magnum. 
They then pierces the dura and arachnoid to enter the subarachnoid space. They 
ascend and when they reach the lower border of pons, they join to form the 
basilar artery. 
Branches : 
1) Meningeal branches 
2) Posterior spinal artery 
3) Anterior spinal artery 
4) Posterior inferior cerebellar artery 
5) Medullary branches 
Basilar artery : 
It is formed by the confluence of the right and left vertebral arteries, and then it 
ascends in a groove on the anterior surface of the pons. When it reaches the 
upper border of pons, it divides into the posterior cerebral arteries. 
The vertebral and basilar arteries together constitute the vertebrobasilar system. 
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Branches of basilar artery : 
1) Pontine arteries 
2) Labyrinthine artery 
3) Anterior inferior cerebellar artery 
4) Superior cerebellar artery 
5) Posterior cerebral artery 
Posterior Cerebral Artery : 
It is the terminal branch of the basilar artery. It curves around the midbrain 
where the posterior communicating artery joins it. 
Cortical branches of the posterior cerebral artery supply the occipital lobes and 
posteromedial temporal lobes. 
Central branches supply the thalamus, lentiform nucleus, midbrain, pineal gland 
and medial geniculate bodies. 
A choroidal branch supplies the choroid plexus of the 3rd ventricle.
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CIRCLE OF WILLIS 
                                  
The circle of willis , also called circulus arteriosus cerebri, is an anastomotic 
system between the 2 internal carotid and the 2 vertebral arteries, which lies in 
the interpeduncular fossa encircling the pituitary stalk. 
Importance – this creates collaterals in the brain circulation. If any part / artery 
of this circle is narrowed or thrombosed, blood flow from the other arteries 
prevent ischemia by preserving the cerebral perfusion. 
Vessels forming the circle of willis – anterior communicating , internal carotid, 
anterior cerebral, posterior communicating, posterior cerebral and basilar 
arteries. 
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ISCHEMIC STROKE 
Ischemic stroke is the result of obstruction of blood flow in a blood vessel 
supplying to an area of the brain. 
2 types : 
1) Thrombotic stroke 
2) Embolic stroke 
Thrombotic stroke – due to a thrombus formed inside the blood vessel. 
It is again divided into 2 – large vessel thrombosis and small vessel 
thrombosis. 
Embolic stroke – due to a blood clot that was formed elsewhere in the body 
circulation, which breaks loose and travels in the circulation to reach the 
brain vessels and causes ischemia of the brain tissue. 
Ischemic strokes are the most common type of strokes and it accounts for 
around 87% of all strokes. 
Incidence of ischemic stroke increases with age and risk factors like 
diabetes, smoking, hypertension, heart disease, dyslipidemia, etc. 
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PATHOPHYSIOLOGY OF ISCHEMIC STROKE  
When there is an acute obstruction of an intracranial blood vessel, there is a 
reduction in blood flow to the particular area it supplies. The physiological and 
anatomical protective mechanisms come into action like autoregulation of 
cerebral blood flow , collateral circulation , etc. These depend on individual 
vascular anatomy, site of occlusion , systemic blood pressure and various other 
factors. When these are overcome, cerebral ischemia ensues. The time take for 
the death of brain tissue depends on the volume of decrease of the cerebral 
blood flow.  
If cerebral blood flow is absent or zero, death of brain tissue occurs in 4 – 10 
minutes. 
Cerebral blood flow  <  16-18 ml/100g tissue/min causes brain tissue death 
within an hour. 
Cerebral blood flow < 20ml/100g/min causes ischemia but not infarction unless 
prolonged for several hours or days. 
Ischemic penumbra – refers to the area surrounding the core region of infarction 
which is ischemic but reversibly dysfunctional. The penumbra remains viable 
due to the collateral supply. If no change in blood flow or restoration of blood 
flow does not occur, the ischemic penumbra will also infarct. 
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MECHANISMS OF ISCHEMIC INJURY : 
1) Cerebral edema leading to increased intracranial tension 
2) Microvascular thrombosis – caused by inflammatory mediators like TNF 
– alpha, interleukins,..etc. 
3) Apoptosis – programmed cell death 
4) Infarction with cell necrosis 
Necrotic cell death is due to –  
1) Loss of ATP stores 
2) Loss of ionic homeostasis – intracellular calcium accumulation 
3) Cell membrane damage due to free radicals 
4) Glutamate and other excitatory neurotoxins 
5) Lactate accumulation leading to intracellular acidosis 
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PARP – poly-A ribose polymerase; iNOS - inducible nitric oxide synthase 
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RISK FACTORS 
 
MODIFIABLE  NON- MODIFIABLE 
Physical inertia Old age 
Smoking  Male gender 
Hypertension Blacks 
Dyslipidemia Positive family history 
Diabetes Mellitus Past history of stroke 
Atrial fibrillation Genetic problems 
Diet   
 
 
 
 
 
CAUSES OF ISCHEMIC STROKE 
A) Thrombosis – lacunar stroke (small vessel), large vessel thrombosis, 
dehydration 
B) Embolic occlusion –  
 Artery to artery – carotid bifurcation, aortic arch, arterial 
dissection 
 Cardioembolic – atrial fibrillation, mural thrombus, myocardial 
infarction, dilated cardiomyopathy, valvular lesions, bacterial 
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endocarditis, paradoxical embolus (ASD, patent foramen ovale ), 
atrial septal aneurysm, spontaneous echo contrast. 
C) Hypercoagulable disorders – protein C deficiency, protein S deficiency, 
antithrombin III deficiency, antiphospholipid syndrome, factor V leiden 
mutation, hyperhomocysteinemia, sickle cell anemia, polycythemia vera, 
SLE, nephrotic syndrome, TTP, IBD, OCPs, etc. 
D) Others – venous sinus thrombosis, fibromuscular dysplasia, vasculitis, 
drugs ( cocaine, amphetamine ), moyamoya disease, eclampsia. 
SIGNS AND SYMPTOMS : 
When a patient comes with an abrupt onset of focal neurological deficit or an 
altered level of consciousness , stroke should be suspected. 
The clinical signs and symptoms vary according to the artery involved and the  
site of lesion in the brain. 
The most common symptoms and signs of stroke are hemiparesis, hemisensory 
loss, altered sensorium, seizures, aphasia, dysarthria, visual disturbances, ataxia, 
vertigo, deviation of angle of mouth, etc. 
These signs and symptoms can occur in isolation but usually they are seen in a 
combination. 
Headache, projectile vomiting , sudden loss of consciousness are more common 
in hemorrhagic strokes.  
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Suspect stroke if there is - 
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COMPLICATIONS OF STROKE 
EARLY ( < 7 DAYS ) LATE ( > 7 DAYS ) 
Cerebral edema, herniation Decubitus ulcer 
Hemorrhagic transformation of 
infarct 
contractures 
Recurrent infarction , increase in size 
of infarct 
Depression, psychological 
disturbances 
Aspiration pneumonitis Decubitus ulcers 
Seizures Aspiration pneumonitis 
Gastrointestinal ulcers, bleeds DVT, pulmonary embolism 
DVT, pulmonary embolism Urinary tract infections 
(catheterisation) 
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APPROACH TO THE PATIENT  
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IMAGING STUDIES : 
1) CT scans – they are the standard imging study for identifying or 
excluding haemorrhage as the cause of stroke. Ischemic strokes 
cannot be reliably picked up by a CT scan in the initial 24-48 
hours. They are also not useful for small ischemic strokes in the 
posterior fossa. Because it is cheaper, faster and more readily 
available than other imaging modalities,  non contrast CT is the 
imaging of choice for acute stroke. 
2) MRI – even though MRI is less sensitive than CT for detecting 
blood, it readily and reliably identifies the location and extent of 
infarcts in all areas of the brain. Early brain infarction can be 
detected by the diffusion weighted sequences and the FLAIR 
sequences. 
3) Cerebral angiography – gold standard for detecting and quantifying 
atherosclerotic stenosis of cerebral arteries. 
4) Xenon CT and PET – used to quantify cerebral blood flow. 
5) Transcranial Doppler – to assess MCA, ACA, PCA and 
vertebrobasilar flow. 
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TREATMENT OF ACUTE ISCHEMIC STROKE 
The treatment aim of acute ischemic stroke is to save the area of ischemic 
penumbra. Tissue plasminogen activator (tPA) is the only FDA approved 
treatment for ischemic strokes. It has to be administered within 3 hours ( 4.5 
hours in select cases ) of onset of symptoms for a beneficial effect. This time 
interval is important, that’s why early identification of sympyoms /signs and 
early hospitalisation is important. Streptokinase is not used because of a higher 
incidence of intracranial haemorrhage and death. 
Endovascular procedures - Mechanical thrombectomy – are also being practised 
in select centres for acute ischemic strokes. 4 devices have been approved for 
mechanical thrombectomy namely Merci Retriever, Penumbra system, Solitaire 
FR Revascularization Device and Trevo. 
325 mg of oral aspirin has also been recommended within 24-48 hours of onset 
of ischemic stroke. 
Primary prevention – use of antiplatelets, statins, dietary modifications and 
exercise in patients with no previous history of stroke and those who are at high 
risk for stroke. 
Secondary prevention – use of antiplatelets, antihypertensives, statins and others 
to prevent recurrence in a patient who already had stroke. 
Physical, occupational and speech therapists also have an important role. 
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HYPERHOMOCYSTEINEMIA AND ISCHEMIC STROKE 
Hyperhomocysteinemia has been found to be an independent risk factor for 
ischemic stroke. Homocysteine levels more than 15 μmol/L is considered to be 
associated with an increased risk of ischemic stroke. 
Hyperhomocysteinemia creates a proatherogenic and prothrombotic 
environment in the blood vessels. 
The main mechanism for this is endothelial cell injury. This initiates the 
atherosclerotic cascade.  
Other mechanisms include disruption of the normal clotting mechanisms by 
inhibition of factor C & antithrombin III and activation of factors 5 ,10 and 12. 
It increases thromboxane A2 synthesis leading to platelet aggregation. It causes 
smooth muscle proliferation, decreases nitric oxide release and increases 
production of free radicals. 
All these factors occurring in the cerebral blood vessels lead to formation of a 
thrombus in these vessels, leading to ischemic stroke. 
Patients with hyperhomocysteinemia in ischemic stroke should undergo routine 
ischemic stroke treatment (tPA/ endoscopic revascularisation/ aspirin) but along 
with that they should receive vitamin supplementation with adequate folic acid 
and vitamin B12 supplements. 
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CAROTID INTIMA MEDIA THICKNESS (CIMT) 
The carotid intima media thickness is now routinely measured by non invasive 
methods like USG, CT, etc. 
B-mode USG is the most commonly used technique for measuring CIMT. It can 
be used to evaluate the carotid lumen diameter and presence & extent of plagues 
as well. 
Increased CIMT has been found to be an early marker of atherosclerosis. It has 
been shown in various studies that increased CIMT is a powerful predictor of 
coronary and cerebrovascular complications. 
Advantages of CIMT by USG – relatively inexpensive, non invasive, no 
radiation hazards and is repeatable. 
CIMT > 0.9 mm is associated with an increased cardiovascular and 
cerebrovascular risk. 
Since homocysteine plays an important role in the pathogenesis  of 
atherosclerosis, CIMT of patients with hyperhomocysteinemia can be used for 
predicting future cardiovascular and cerebrovascular problems. It has been 
found that homocysteine levels correlate with their CIMT measurements. 
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TECHNIQUE : 
CIMT represents the combined thickness of the intima and media layers of the 
common carotid artery. 
During routine ultrasound study, the carotid is divided into 3 segments, each 
segment measuring around 1 cm in length : 
1) The common carotid artery just prior to its bifurcation 
2) The carotid bulb at its bifurcation point 
3) Proximal 1 cm of the Internal carotid. 
The common carotid artery just prior to its bifurcation is the most commonly 
used area to measure CIMT. 
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The typical B-mode image shows 2 parallel echogenic lines separated by a 
hypoechoic space. These lines are the lumen-intima interface and the media-
adventitia interface. Border detection programs are used to measure this space, 
they trace the leading edges of the lumen-intima to the leading edge of media-
adventitia, and thus calculate the CIMT.  
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III. AIMS AND OBJECTIVES 
1. To study the clinical profile of ischemic stroke at Government Stanley 
Hospital, Chennai. 
2. To study prevalence of hyperhomocysteinemia in these patients and correlate 
with carotid intima media thickness in these patients. 
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IV. MATERIALS AND METHODS 
Place of study: 
Department of general medicine,  medical OPD and medical wards,  Stanley 
medical college and hospital, Chennai. 
Duration: 
November 2013 to September 2014. 
Study design: 
Prospective  observational study 
Patient selection: 
Any patient with  ischemic stroke in medical OPD and medical wards.  
 
Sample size : 
75 patients 
 
Ethical committee approval 
Ethical committee approval was obtained for the study  
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Methodology 
Patients admitted with symptoms suggestive of ischemic stroke, which is 
proved later by CT brain, will undergo serum homocysteine measurements and 
carotid USG to measure carotid intima media thickness. The study will be 
aimed at observing the prevalence of hyperhomocysteinemia in ischemic stroke 
and also whether there is any correlation between the serum homocysteine 
levels and carotid intima media thickness. 
 
Exclusion criteria: 
Hemorrhagic stroke, patients on folic acid supplements, patients on anti-
epileptics/ OCPs/ drugs causing hyperhomocysteinemia, chronic kidney disease, 
pre-existing coronary artery disease 
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Stastical analysis 
Data will be analysed with SPSS software version 16.0 for windows.  
All continuous data will be expressed as mean and sd and will be analysed using 
students t test.  
Categorical data will be expressed as number (percentage) and analysed by chi 
square or fishers exact test.  
Pearson's correlation coefficient and linear regression analysis will be 
undertaken to establish correlation and regression among variables.  
P value of <0.05 was considered as statistically significant 
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CONSENT 
The study group thus identified by the above criteria (inclusion and exclusion 
criteria) was first instructed about the nature of the study. Willing participants 
were taken up for this study after getting a written / informed consent from these 
patients or their relatives in the local vernacular language. 
STUDY SUBJECTS 
All   the  patients  who  fulfilled  the  inclusion  criteria were  included  in  this  
study. The  included  patients were subjected to detailed history taking, 
complete physical examination  and  the  relevant  laboratory  investigations  as 
per a proforma, exclusively  designed  for  the  study. 
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V. RESULTS AND DISCUSSION 
 
STATISTICAL ANALYSIS 
 
Descriptive statistics was done for all data and suitable statistical tests of 
comparison were done. Continuous variables were analysed with the student’s t 
test and categorical variables were analysed with the Chi-Square Test and Fisher 
Exact Test. Statistical significance was taken as P < 0.05. The data was analysed 
using EpiInfo software (7.1.0.6 version; Center for disease control, USA) and 
Microsoft Excel 2010. 
 
 
SAMPLE SIZE CALCULATION 
 
Sample size was determined on the basis of a pilot study in which the difference 
in carotid intimal thickness in serum homocysteine groups was measured at 4%.  
We calculated a minimum sample size of 59 patients was required, assuming a 
type 1 error (two-tailed) of 0.05 and a margin of error of 10%. Therefore, the final 
sample selected was n= 75. 
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n= t² x p(1-p) 
  m² 
Description: 
n = required sample size 
t = confidence level at 95% (standard value of 1.96) 
p = estimated prevalence of malnutrition in the project area 
m = margin of error at 10% (standard value of 0.05) 
 
n = (1.96)² x 0.04(10865) 
              (0.05)² 
 
n = 3.8146 x 0.0384 
  
       0.0025 
= 59 
= 75 samples in the study 
group 
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AGE 
 
 
 
Age Distribution 
S. HOM ≤ 
15µmol/L 
% 
S. HOM > 
15µmol/L 
% 
≤ 30 years 2 9.52 4 7.41 
31 to 45 years 3 14.29 16 29.63 
46 to 60 years 9 42.86 11 20.37 
61 to 75 years 4 19.05 17 31.48 
76 to 90 years 3 14.29 6 11.11 
Total 21 100 54 100 
 
 
Age Distribution S. HOM ≤ 15µmol/L S. HOM > 15µmol/L 
N 21 54 
Mean 55.66667 55.87037 
SD 14.51666 16.75128 
P value 
Unpaired  
t- test 
0.9586 
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By conventional criteria the association between the serum homocysteine groups 
and age is considered to be not statistically significant since p > 0.05. 
 
GENDER 
 
 
 
Gender Distribution 
S. HOM ≤ 
15µmol/L 
% 
S. HOM > 
15µmol/L 
% 
Male 7 33.33 39 72.22 
Female 14 66.67 15 27.78 
Total 21 100 54 100 
Chi-square Statistic 9.64  
Degrees of freedom 1 
P value 
Chi Squared Test 
.200 
 
By conventional criteria the association between the serum homocysteine groups 
and Gender is considered to be not statistically significant since p > 0.05. 
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Since age and gender is not statistically significant, it means that there is no 
difference between the groups. In other words the groups contain subjects with 
the same basic demographic characteristics. 
Risk Factors 
Smoking 
 
 
 
Smoking 
S. HOM ≤ 
15µmol/L 
% S. HOM > 15µmol/L 
Absent 19 90.48 31 57.41 
Present 2 9.52 23 42.59 
Total 21 100 54 100 
Chi-square Statistic 9.41  
Degrees of freedom 1 
P value 
Chi Squared Test 
0.002 
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By conventional criteria the association between the serum homocysteine groups 
and smoking  is considered to be statistically significant since p < 0.05. 
Statistical Significance 
 
This indicates that there is a true difference among the study groups and the 
difference is significant.  
In simple terms,  while studying hyperhomocysteinemia in ischemic stroke 
patients, the incidence of smoking is  2 in patients with serum homocysteine 
levels ≤ 15µmol/L and 23 in patients with  serum homocysteine levels > 
15µmol/L with a p-value of 0.002 according to Chi-Squared test. 
 
Clinical Significance 
 
The incidence of smoking among ischemic stroke patients with serum 
homocysteine levels ≤ 15µmol/L was meaningfully less(9.52%) compared to in 
patients with serum homocysteine levels > 15µmol/L(42.59%).  This difference 
is true and significant and has not occurred by chance. 
Conclusion  
We conclude that majority of the smokers are associated with higher serum 
homocysteine levels > 15µmol/L in ischaemic stroke patients.  This also proves 
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there is an increasing trend of having higher serum homocysteine levels among 
smokers in our study. 
 
Alcoholism  
 
 
 
Alcoholism 
S. HOM ≤ 
15µmol/L 
% S. HOM > 15µmol/L 
Absent 19 90.48 36 66.67 
Present 2 9.52 18 33.33 
Total 21 100 54 100 
Chi-square Statistic 4.38  
Degrees of freedom 1 
P value 
Chi Squared Test 
0.036 
 
By conventional criteria the association between the serum homocysteine groups 
and alcoholism is considered to be statistically significant since p < 0.05. 
Statistical Significance 
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This indicates that there is a true difference among the study groups and the 
difference is significant.  
In simple terms,  while studying hyperhomocysteinemia in ischemic stroke 
patients, the incidence of alcoholism is  2 in patients with serum homocysteine 
levels ≤ 15µmol/L and 18 in patients with  serum homocysteine levels > 
15µmol/L with a p-value of 0.036 according to Chi-Squared test. 
 
Clinical Significance 
 
The incidence of alcoholism among ischemic stroke patients with serum 
homocysteine levels ≤ 15µmol/L was meaningfully less(9.52%) compared to in 
patients with serum homocysteine levels > 15µmol/L(33.33%).  This difference 
is true and significant and has not occurred by chance. 
Conclusion  
We conclude that alcoholism in our study is associated with higher serum 
homocysteine levels > 15µmol/L in ischaemic stroke patients.  This also proves 
there is an increasing trend of having higher serum homocysteine levels among 
patients suffering from alcoholism in our study. 
  
84 
 
Hypertension  
 
 
 
Hypertension 
S. HOM ≤ 
15µmol/L 
% S. HOM > 15µmol/L 
Absent 16 76.19 40 74.07 
Present 5 23.81 14 25.93 
Total 21 100 54 100 
Chi-square Statistic 0.358 
Degrees of freedom 1 
P value 
Chi Squared Test 
0.850 
 
By conventional criteria the association between the serum homocysteine groups 
and hypertension is considered to be not statistically significant since p > 0.05. 
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Diabetes  
 
 
 
Diabetes 
S. HOM ≤ 
15µmol/L 
% S. HOM > 15µmol/L 
Absent 16 76.19 42 77.78 
Present 5 23.81 12 22.22 
Total 21 100 54 100 
Chi-square Statistic 0.217 
Degrees of freedom 1 
P value 
Chi Squared Test 
0.883 
 
By conventional criteria the association between the serum homocysteine groups 
and diabetes mellitus is considered to be not statistically significant since p > 
0.05. 
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DYSLIPIDEMIA 
 
 
 
Dyslipidaemia 
S. HOM ≤ 
15µmol/L 
% S. HOM > 15µmol/L 
Absent 20 95.24 47 87.04 
Present 1 4.76 7 12.96 
Total 21 100 54 100 
Chi-square Statistic 1.07  
Degrees of freedom 1 
P value 
Chi Squared Test 
0.302 
 
By conventional criteria the association between the serum homocysteine groups 
and hyperlipidaemia is considered to be not statistically significant since p > 0.05. 
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Glasgow Coma Scale 
 
 
 
Brain Injury 
Glasgow 
Coma Scale 
S. HOM ≤ 
15µmol/L 
% 
S. HOM > 
15µmol/L 
% 
Severe Brain Injury ≤ 8 0 0.00 0 0.00 
Moderate Brain Injury 9 to 12 8 38.10 19 35.19 
Mild Brain Injury ≥ 13 13 61.90 35 64.81 
Total 21 100 54 100 
Chi-square Statistic 0.556 
Degrees of freedom 1 
P value 
Chi Squared Test 
0.814 
 
By conventional criteria the association between the serum homocysteine groups 
and Glasgow coma scores are considered to be not statistically significant since 
p > 0.05. 
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Clinical Profile 
 
 
 
Clinical Profile 
S. HOM ≤ 
15µmol/L 
% 
S. HOM > 
15µmol/L 
% 
P value 
Chi 
Squared 
Test 
Hemiparesis / Hemiplegia 7 33.33 34 62.96 0.021 
Hemisensory Loss 3 14.29 2 3.70 0.099 
Cerebellar Symptoms 5 23.81 5 9.26 0.096 
Seizures 1 4.76 2 3.70 0.834 
Encephalopathy 5 23.81 11 20.37 0.744 
Total 21 100 54 100  
 
By conventional criteria the association between the serum homocysteine groups 
and clinical features like hemisensory loss, cerebellar symptoms, seizures and 
encephalopathy are considered to be not statistically significant since p > 0.05. 
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By conventional criteria the association between the serum homocysteine groups 
and hemiparesis/hemiplegia is considered to be statistically significant since p < 
0.05. 
Statistical Significance 
 
This indicates that there is a true difference among the study groups and the 
difference is significant.  
In simple terms,  while studying hyperhomocysteinemia in ischemic stroke 
patients, the incidence of hemiparesis/hemiplegia is  7 in patients with serum 
homocysteine levels ≤ 15µmol/L and 34 in patients with  serum homocysteine 
levels > 15µmol/L with a p-value of 0.021 according to Chi-Squared test. 
 
Clinical Significance 
 
The incidence of hemiparesis/hemiplegia among ischemic stroke patients with 
serum homocysteine levels ≤ 15µmol/L was meaningfully less(17.07%) 
compared to in patients with serum homocysteine levels > 15µmol/L(82.93%).  
This difference is true and significant and has not occurred by chance. 
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Conclusion  
We conclude that hemiparesis/hemiplegia in our study is associated with higher 
serum homocysteine levels > 15µmol/L in ischaemic stroke patients.  This also 
proves there is an increasing trend of having higher serum homocysteine levels 
among patients suffering from hemiparesis/hemiplegia in our study. 
 
Site of Infarct 
 
 
 
Site of Infarct 
S. HOM ≤ 
15µmol/L 
% S. HOM > 15µmol/L 
Carotid 13 61.90 48 88.89 
Vertebral 8 38.10 6 11.11 
Total 21 100 54 100 
Chi-square Statistic 7.25  
Degrees of freedom 1 
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P value 
Chi Squared Test 
0.007 
 
By conventional criteria the association between the serum homocysteine groups 
and site of infarct is considered to be statistically significant since p < 0.05. 
Statistical Significance 
 
This indicates that there is a true difference among the study groups and the 
difference is significant.  
In simple terms,  while studying hyperhomocysteinemia in ischemic stroke 
patients, the incidence of infarct in carotid artery is  13 in patients with serum 
homocysteine levels ≤ 15µmol/L and 48 in patients with  serum homocysteine 
levels > 15µmol/L with a p-value of 0.007 according to Chi-Squared test. 
 
Clinical Significance 
 
The incidence of infarct in carotid artery among ischemic stroke patients with 
serum homocysteine levels ≤ 15µmol/L was meaningfully less(61.90%) 
compared to in patients with serum homocysteine levels > 15µmol/L(89.99%).  
This difference is true and significant and has not occurred by chance. 
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Conclusion  
We conclude that infarcts in carotid artery in our study is associated with higher 
serum homocysteine levels > 15µmol/L in ischaemic stroke patients.  This also 
proves there is an increasing trend of having higher serum homocysteine levels 
among patients suffering from infarct in carotid artery in our study. 
 
Duration of Hospital Stay 
 
 
 
Duration of Hospital Stay 
S. HOM ≤ 
15µmol/L 
% 
S. HOM > 
15µmol/L 
% 
< 2 weeks 13 61.90 28 51.85 
2 weeks to 1 month 6 28.57 15 27.78 
> 1 month 2 9.52 11 20.37 
Total 21 100 54 100 
Chi-square Statistic 1.31  
Degrees of freedom 2 
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P value 
Chi Squared Test 
0.520 
 
By conventional criteria the association between the serum homocysteine groups 
and duration of stay in hospital are considered to be not statistically significant 
since p > 0.05. 
 
Serum Homocysteine  
 
 
 
Serum 
Homocysteine 
All % 
S. HOM ≤ 
15µmol/L 
% 
S. HOM > 
15µmol/L 
% 
≤ 15µmol/L 21 28.00 21 100.00 0 0.00 
16 to 30 µmol/L 37 49.33 0 0.00 37 68.52 
> 30 µmol/L 17 22.67 0 0.00 17 31.48 
Total 75 100 21 100 54 100 
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Serum Homocysteine All 
S. HOM ≤ 
15µmol/L 
S. HOM > 
15µmol/L 
N 75 21 54 
Mean 24.19 11.99 28.93 
SD 12.25 1.71 11.25 
P value 
Unpaired  
t- test 
0.000 
 
By conventional criteria the association between the serum homocysteine groups 
is considered to be statistically significant since p < 0.05. 
Statistical Significance 
 
This indicates that there is a true difference among the study groups and the 
difference is significant.  
In simple terms,  while studying hyperhomocysteinemia in ischemic stroke 
patients, the average serum homocysteine values in serum homocysteine levels 
≤ 15µmol/L group is 11.99±1.71 µmol/L and in serum homocysteine levels > 
15 µmol/L group is 28.93±11.25 µmol/L with a p-value of 0.000 according to 
Unpaired t test. 
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Clinical Significance 
 
The average serum homocysteine values among ischemic stroke patients with 
serum homocysteine levels ≤ 15µmol/L was meaningfully 2.41 times less 
compared to in patients with serum homocysteine levels > 15µmol/L with a 
difference of 16.94 µmol/L .  This difference is true and significant and has not 
occurred by chance. 
 
Carotid Intimal Thickness  
 
 
 
Carotid Intimal 
Thickness 
All % 
CIT ≤ 0.9 
mm 
% 
CIT > 0.9 
mm 
% 
< 0.75 mm 24 32.00 24 114.29 0 0.00 
0.76 to 0.79 mm 3 4.00 3 14.29 0 0.00 
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0.8 to 0.89 mm 11 14.67 11 52.38 0 0.00 
≥ 0.9 mm 37 49.33 0 0.00 54 100.00 
Total 75 100 38 180.9524 54 100 
 
Carotid Intimal 
Thickness 
All CIT ≤ 0.9 mm CIT > 0.9 mm 
N 75 38 54 
Mean 24.19 0.71 1.25 
SD 12.25 0.08 0.16 
P value 
Unpaired  
t- test 
0.000 
 
By conventional criteria the association between the carotid intimal thickness 
groups is considered to be statistically significant since p < 0.05. 
Statistical Significance 
 
This indicates that there is a true difference among the study groups and the 
difference is significant.  
In simple terms, while studying hyperhomocysteinemia in ischemic stroke 
patients, the average carotid intimal thickness values in CIT ≤ 0.9 mm group is 
0.71±0.08 mm and in CIT > 0.9 mm group is 1.25±0.16 mm with a p-value of 
0.000 according to Unpaired t test. 
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Serum Homocysteine Vs Carotid Intimal Thickness 
 
 
 
 
Carotid Intimal 
Thickness 
S. HOM ≤ 
15µmol/L 
% 
S. HOM > 
15µmol/L 
% 
< 0.75 mm 17 80.95 7 12.96 
0.76 to 0.79 mm 1 4.76 2 3.70 
0.8 to 0.89 mm 2 9.52 9 16.67 
≥ 0.9 mm 1 4.76 36 66.67 
Total 21 100 54 100 
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Carotid Intimal Thickness S. HOM ≤ 15µmol/L S. HOM > 15µmol/L 
N 21 54 
Mean 0.69 1.05 
SD 0.13 0.26 
P value 
Unpaired  
t- test 
0.0000 
 
 
Pearson’s Correlation   Serum Homocysteine 
(µmol/L) 
Carotid Intimal 
Thickness (in mm) 
Serum Homocysteine (µmol/L) 1  
Carotid Intimal Thickness (in mm) -0.798708376 1 
 
By conventional criteria the association between the serum homocysteine groups 
carotid intimal thickness values are considered to be statistically significant since 
p < 0.05. 
Statistical Significance 
 
This indicates that there is a true difference among the study groups and the 
difference is significant.  
In simple terms,  while studying hyperhomocysteinemia in ischemic stroke 
patients, the average carotid intimal thickness values in serum homocysteine 
levels ≤ 15µmol/L group is 0.69±0.13 mm and  in serum homocysteine levels > 
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15 µmol/L group is 1.05±0.26 mm with a p-value of 0.0000 according to 
Unpaired t test. 
There is a strong positive correlation between serum homocysteine levels and 
carotid intimal thickness measurements. This is indicated by the Pearson's R 
Correlation value of -0.798708376. This means as serum homocysteine increases 
the carotid intimal thickness measurement increase in ischaemic stroke patients 
 
Clinical Significance 
 
The average carotid intimal thickness values among ischemic stroke patients 
with serum homocysteine levels ≤ 15µmol/L was meaningfully less 1.52 times 
less compared to in patients with serum homocysteine levels > 15µmol/L with a 
reduction of 0.36 mm .  This difference is true and significant and has not 
occurred by chance. 
The increase in carotid intimal thickness measurements in ischemic stroke 
patients correlates positively, directly and strongly with the serum homocysteine 
levels. This means that the 66.67% increase in patients with CIT ≥ 0.9 mm  in 
serum homocysteine levels > 15µmol/L group smoking is true 79.87% of times 
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Similarly in carotid intimal thickness measurements in ischemic stroke patients 
the 80.95% decrease in patients with CIT < 0.75 mm in serum homocysteine 
levels ≤ 15µmol/L group smoking is true 79.87% of times 
 
Conclusion  
We conclude that in our study the patients with higher carotid intimal thickness 
are associated with higher serum homocysteine levels (> 15µmol/L) in ischaemic 
stroke patients.  This also proves there is an increasing trend of having higher 
serum homocysteine levels among patients with higher carotid intimal thickness 
in our study. 
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VI. CITATIONS 
1. The Northern Manhattan study ,by the department of neurology in 
Columbia university in New York USA, studied the correlation between 
homocysteine and ischemic stroke found out that total homocysteine 
levels more than 15 micromole/l is an independent risk factor for 
ischemic cerebrovascular diseases.  They also found that these effects are 
more in whites and Hispanics. But homocysteine levels between 10 and 
15 micromol/l were less predictive. 
2. The Rotterdam study , by Michiel L. Bots et al, studied whether carotid 
intima medial thickness was associated with an increased future risk of 
cerebrovascular and cardiovascular diseases, and they concluded at the 
end of their study that an increased common carotid intima media 
thickness is associated with future cardiovascular and cerebrovascular 
events. 
3. Venkatasubramanian et al studied the relation between 
hyperhomocysteinemia and risk of ischemic stroke in young Asian adults 
, and they also concluded that there is a strong, graded and significant 
relationship between stroke risk and hyperhomocysteinemia., and the 
proatherogenic effect of homocysteine is responsible for the increased 
incidence of stroke in these people. 
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4. The Atherosclerosis Risk in Communities (ARIC) study, by Chambless et 
al, also demonstrated hyperhomocysteinemia was associated with an 
increased risk  for thickening of the carotid artery intima media wall. 
5. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS) 
associated carotid intima media thickness with homocysteine levels in 
asymptomatic patients. 
6. Voutilainen et al also found an association between plasma total 
homocysteine and increased common carotid artery thickness using B-
mode USG, in Finnish people. 
7. In India, the Ruby Hall study in Pune and another independent study done 
in Guwahati demonstrated hyperhomocysteinemia in ischemic stroke. 
The Ruby Hall study estimated serum homocysteine, folate and vit B12 in 
ischemic stroke patients, and they found ~74 % of arterial strokes had 
increased homocysteine. The Guwahati study demonstrated ~ 60% 
patients had hyperhomocysteinemia. 
8. Homocysteine and Atherosclerosis Reduction Trial (HART) done in 
Japan demonstrated an association between elevated homocysteine and 
increased common carotid media thickness. 
9. P Poredos et al demonstrated that carotid intima media thickness is a 
measure of extent of atherosclerosis  and is an indicator for 
cardiovascular and stroke risk.  
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10. In the Journal of Hypertension (feb 2002), the importance of carotid 
intima media thickness was discussed as a new tool for diagnosis and 
treatment of cardiovascular risk. They noted that increased intima media 
thickness is a powerful predictor of cardiac and cerebrovascular 
complications.  
11. A case control study done in JIPMER, India , in 2009, regarding 
common carotid intima media thickness in acute ischemic stroke, found 
that patients with ischemic stroke had a significantly higher intimal 
thickness as compared to controls. 
12. A recent study published in Neurology journal in October 2013 showed a 
meta-analysis on vitamin B supplementation, homocysteine levels and 
risk of cerebrovascular diseases, in which 14 RCTs were studied and they 
concluded that vitamin B supplementation for homocysteine reduction 
significantly reduced stroke levels. 
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 VII. CONCLUSION 
Hyperhomocysteinemia is closely related to ischemic stroke. It has been 
recognised as a prothrombotic and proatherosclerotic state and is attributed as 
one of the causes of ischemic stroke. 
In my study, the prevalence of hyperhomocysteinemia in patients with ischemic 
stroke was 54 out of 75 patients ,ie. 72 %. It correlates with various other Indian 
studies done elsewhere.  
It was also found that serum homocysteine levels correlated with alcoholism 
and smoking as p values were significant ( <0.05 ). 
 The correlation of homocysteine to age, gender, diabetes, hypertension, 
dyslipidemia, glasgow coma scale score at time of presentation and the duration 
of hospital stay was not statistically significant. 
The clinical profile of ischemic stroke patients getting admitted in Government 
Stanley Hospital, Chennai revealed that the most common presentation during 
admission is a hemiplegia/hemiparesis (41 patients out of 75). Other 
presentations in decreasing order of frequency include acute encephalopathy 
followed by cerebellar symptoms, hemisensory loss and seizures. 
A statistically significant correlation was found between the serum 
homocysteine levels and hemiparesis/hemiplegia, and also the site of infarct, as 
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majority of the anterior circulation strokes involving the carotid artery, was 
found to have a significantly elevated homocysteine values. 
My study also found a statistically significant positive correlation between the 
serum homocysteine levels and the carotid intima media thickness. 
As per previous studies elsewhere as given in the citations, and my study, I 
conclude that there is a high prevalence of hyperhomocysteinemia in ischemic 
stroke patients and also the patients with higher carotid intimal thickness are 
associated with higher serum homocysteine levels (> 15µmol/L) in ischaemic 
stroke patients. 
More studies with similar indices have to be done to confirm the results. 
I also conclude that homocysteine measurements and carotid intima media 
thickness measurements in ischemic stroke patients are warranted. 
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CLINICAL PROFILE 
 
 
 
 
MOTOR WEAKNESS CHEST PAIN 
SENSORY DISTURBANCES DYSPNEA 
ALTERED SENSORIUM PEDAL EDEMA 
CRANIAL NERVE DISTURBANCES COUGH / HEMOPTYSIS 
LOSS OF CONSCIOUSNESS PALPITATIONS 
HEADACHE  SYNCOPE 
VOMITING FEVER 
SEIZURES OLIGURIA 
 
 
NAME 
 
 
AGE /SEX:  
OCCUPATION:  
ADDRESS WITH CONTACT NO: 
 
 
IP NO/OP NO:  
DATE OF ADMISSION:  
DATE OF DISCHARGE 
 
 
PERSONAL H/O : 
SMOKER  ALCOHOLIC  
 
PAST H/O : 
DIABETES  EPILEPTIC  
HYPERTENSION  DYSLIPIDEMIA  
CAD  CVA  
 
 
EXAMINATION :  
PALLOR  CVS  
ICTERUS  RS  
PEDAL EDEMA  P/A  
BP  CNS  
PR    
 
 
 
 
 
 
 
 
 
CNS EXAMINATION : 
 
HIGHER MENTAL FUNCTIONS : 
CRANIAL NERVES : 
SPINOMOTOR SYSTEM : 
                                                                  RIGHT                        LEFT 
 POWER -  UPPER LIMBS 
                             LOWER LIMBS 
 TONE –     UPPER LIMBS 
                             LOWER LIMBS 
 BULK –      UPPER LIMBS 
                             LOWER LIMBS 
 SUPERFICIAL REFLEXES 
 DEEP TENDON REFLEXES 
 PLANTAR 
 GAIT 
 INVOLUNTARY MOVEMENTS 
 
SENSORY SYSTEM : 
CEREBELLUM : 
DORSAL COLUMN : 
AUTONOMIC NEERVOUS SYSTEM : 
SPINE AND CRANIUM : 
SIGNS OF MENINGEAL IRRITATION : 
FEATURES OF INCREASED INTRACRANIAL TENSION : 
INVESTIGATIONS 
Hb  
 TC  
DC  
PLATELETS  
ESR  
PCV  
RBS  
UREA  
CREATININE  
Na+  
K+  
Cl-  
TOTAL BILIRUBIN  
DIRECT BILIRUBIN  
PROTEINS  
ALBUMIN  
SGOT  
SGPT  
ALP  
TOTAL CHOLESTEROL  
TRIGLYCERIDES  
HDL  
LDL  
VLDL  
ECG  
ECHOCARDIOGRAM  
CT BRAIN  
SERUM HOMOCYSTEINE  
CAROTID INTIMAL THICKNESS  
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MASTER CHART 
S. 
NO 
AGE SE
X 
RISK 
FACT
ORS 
GCS CLINI
CAL 
PROF
ILE 
CT 
BRAIN 
SERUM 
HOMOCY
STEINE 
(µmol/L) 
 
CAROTID 
INTIMAL 
THICKNESS 
(in mm) 
DURATI
ON OF 
HOSPIT
AL 
STAY 
1 63 M 1, 3 15 A 1 27.3 0.95 A 
2 55 F - 15 A 1 26.9 0.81 A 
3 58 M 2 14 E 1 39.3 1.30 B 
4 32 M 1 11 E 1 41.1 1.12 C 
5 35 F - 15 A 1 22.0 0.60 A 
6 44 M - 15 B 1 11.3 0.58 A 
7 41 M 4 15 C 2 33.5 1.08 A 
8 77 F 4 12 E 1 14.0 0.68 B 
9 84 M 1,3,4 10 E 1 26.2 1.20 C 
10 29 F - 15 A 1 42.0 1.34 B 
11 54 F 4 15 B 1 11.0 0.65 A 
12 58 M 1,2 10 E 2 13.4 0.82 C 
13 62 M 2,3 14 C 2 44.6 1.40 B 
14 30 M - 15 A 2 75.9 1.42 B 
15 42 F - 15 A 1 11.3 0.62 A 
16 75 M 1,2,5 11 E 1 52.7 1.40 C 
17 67 F 3 14 C 2 13.0 0.64 A 
18 68 M 1,4,5 10 E 1 57.3 1.42 C 
19 55 F 3,4,5 15 A 1 41.2 1.20 A 
20 43 F - 15 A 1 27.3 0.72 A 
21 51 M - 15 A 1 22.2 0.70 A 
22 54 M 1 14 A 1 29.2 0.80 A 
23 53 F - 15 B 1 13.0 0.64 A 
24 41 F 5 15 A 1 19.3 0.70 A 
25 55 M 1 13 A 1 11.1 0.62 A 
26 71 M 3,4,5 9 E 1 13.9 1.20 C 
27 80 F 3 11 E 2 10.3 0.68 B 
28 29 M 2 15 A 1 8.3 0.62 A 
29 40 M 1,2 14 A 1 33.8 1.20 A 
30 70 M 3 12 D 1 31.7 1.16 B 
31 65 F - 15 A 2 12.2 0.62 A 
32 52 M - 15 A 1 31.1 1.00 A 
33 41 M 1 14 C 2 21.0 0.82 A 
34 45 F - 13 A 1 23.3 0.84 B 
35 54 M 3 13 A 1 17.2 0.68 B 
36 53 M - 15 A 1 15.5 0.64 A 
37 86 M 3,5 11 E 1 29.2 1.32 C 
38 27 F - 15 A 1 31.1 1.20 A 
39 39 M - 13 A 1 27.3 1.15 B 
40 62 F - 15 C 2 22.2 0.78 A 
41 71 F - 14 B 1 18.3 0.80 A 
42 80 M 2 10 E 1 27.6 1.22 C 
43 33 M 1 14 A 1 22.4 1.02 A 
44 57 F - 11 D 1 12.9 0.80 B 
45 63 M 1,2 14 A 1 22.3 0.82 A 
46 30 M 1,2 11 A 1 18.2 0.80 B 
47 49 M - 10 C 2 13.3 0.70 B 
48 70 M 2 11 A 1 30.0 1.40 B 
49 74 F 4 9 E 1 21.1 1.24 C 
50 60 M 3,4,5 10 A 1 22.1 1.26 C 
51 62 F 4 15 A 1 13.9 0.64 A 
52 42 F 3,4 14 C 2 16.2 0.66 A 
53 39 M 1,2 11 A 1 39.3 1.44 C 
54 77 M 1,2 12 A 1 33.2 1.32 B 
55 43 F 3 14 C 2 11.2 0.62 A 
56 88 M 3,4,5 9 E 1 19.9 1.00 B 
57 60 M 1 15 A 1 21.3 0.80 A 
58 52 F - 14 C 2 8.1 0.64 A 
59 61 M 1 14 A 1 29.1 1.12 A 
60 45 M 1,2 15 A 1 25.1 1.08 A 
61 50 M - 11 E 1 13.8 0.66 B 
62 38 M 1,2 10 A 1 39.1 1.52 C 
63 82 F 3,4 12 A 1 18.2 0.92 B 
64 75 M 1,2,3 14 A 1 24.2 0.96 A 
65 40 M 1,2 14 A 1 25.8 1.02 A 
66 51 F - 15 C 2 11.2 0.64 A 
67 71 M 2,4 14 B 1 18.2 0.76 A 
68 56 F 3 10 E 1 16.3 0.80 B 
69 70 M 1,2,4 9 E 1 28.2 1.44 C 
70 29 F - 15 A 1 11.4 0.62 A 
71 81 F 3,4 12 A 1 13.2 0.78 B 
72 40 M 1,2 15 A 1 29.1 1.12 A 
73 70 F - 10 D 1 19.2 1.00 B 
74 65 M 1,2,3 14 A 1 27.7 1.10 A 
75 72 M 1,2 15 A 1 38.6 1.28 A 
 
ABBREVIATIONS : 
 
SEX : 
M – MALE 
F – FEMALE 
 
RISK FACTORS :  
1 – SMOKING 
2 – ALCOHOLISM 
3 – HYPERTENSION 
4 – DIABETES MELLITUS 
5 – DYSLIPIDEMIA  
 
 GCS – GLASGOW COMA SCALE  
    Maximum score = 15 
    Minimum score = 3 
 
CLINICAL PROFILE : 
A – HEMIPARESIS / HEMIPLEGIA 
B – HEMISENSORY LOSS 
C – CEREBELLAR SYMPTOMS 
D – SEIZURES  
E - ENCEPHALOPATHY 
 
CT BRAIN : 
1 – INFARCT IN ANTERIOR CIRCULATION ( CAROTID ) 
2 – INFARCT IN POSTERIOR CIRCULATION ( VERTEBRAL ) 
 
DURATION OF HOSPITAL STAY : 
A – LESS THAN 2 WEEKS 
B – 2 WEEKS TO 1 MONTH 
C – MORE THAN 1 MONTH 
 
 
